Intravenous palivizumab in respiratory syncytial virus infection after hematopoietic stem cell transplant in children
MetadataShow full item record
Respiratory syncytial virus (RSV) infection can cause lower respiratory tract disease and mortality in pediatric hematopoietic stem cell transplant (HSCT) recipients. We report two children who underwent HSCT and developed RSV infection simultaneously at the Bone Marrow Transplant Unit. The treatment with intravenous palivizumab was provided and sequential viral loads were measured in nasopharyngeal (NP) and whole blood samples. To our knowledge, this is the first report where RSV loads were measured in parallel (NP and blood), before and after palivizumab, in correlation with a favorable clinical outcome in both cases.
Artículo de publicación ISI
Quote ItemPediatr Blood Cancer. 2017; e26667
The following license files are associated with this item: